| Schedule of adjustments on the restated financial statements consolidated balance sheet |
| Consolidated Balance Sheet as of March 31, 2022 |
|
As
Previously Reported |
|
|
Adjustment |
|
|
As
Restated |
|
| Accounts payable and accrued liabilities |
|
$ |
43,933 |
|
|
$ |
1,028 |
|
|
$ |
44,961 |
|
| Other liabilities |
|
$ |
81,948 |
|
|
$ |
9,933 |
|
|
$ |
91,881 |
|
| Total liabilities |
|
$ |
371,146 |
|
|
$ |
10,961 |
|
|
$ |
382,107 |
|
| Redeemable convertible preferred stock (Series A) |
|
$ |
194,675 |
|
|
$ |
(1,028 |
) |
|
$ |
193,647 |
|
| Additional paid-in capital |
|
$ |
723,394 |
|
|
$ |
(1,346 |
) |
|
$ |
722,048 |
|
| Accumulated deficit |
|
$ |
(470,304 |
) |
|
$ |
(8,587 |
) |
|
$ |
(478,891 |
) |
| Total stockholders’ equity |
|
$ |
243,414 |
|
|
$ |
(9,933 |
) |
|
$ |
233,481 |
|
| Consolidated Balance Sheet as of December 31, 2021 |
|
As
Previously Reported |
|
|
Adjustment |
|
|
As
Restated |
|
| Other liabilities |
|
$ |
26,585 |
|
|
$ |
11,550 |
|
|
$ |
38,135 |
|
| Total liabilities |
|
$ |
258,304 |
|
|
$ |
11,550 |
|
|
$ |
269,854 |
|
| Additional paid-in capital |
|
$ |
708,175 |
|
|
$ |
(6,941 |
) |
|
$ |
701,234 |
|
| Accumulated deficit |
|
$ |
(465,264 |
) |
|
$ |
(4,609 |
) |
|
$ |
(469,873 |
) |
| Total stockholders’ equity |
|
$ |
233,234 |
|
|
$ |
(11,550 |
) |
|
$ |
221,684 |
|
|
| Schedule of adjustments on the restated financial statements consolidated statement of operations |
| Consolidated Statement of Operations for the Three Months Ended March 31, 2022 |
|
As
Previously
Reported |
|
|
Adjustment |
|
|
As
Restated |
|
| |
|
(amounts in thousands except share
and per share amounts) |
|
| Change in fair value of contingent consideration from mergers and acquisitions |
|
$ |
(682 |
) |
|
$ |
(3,978 |
) |
|
$ |
(4,660 |
) |
| Net loss before income taxes |
|
$ |
(34,417 |
) |
|
$ |
(3,978 |
) |
|
$ |
(38,395 |
) |
| Net loss |
|
$ |
(6,000 |
) |
|
$ |
(3,978 |
) |
|
$ |
(9,978 |
) |
| Net loss attributable to common shareholders |
|
$ |
(7,028 |
) |
|
$ |
(3,978 |
) |
|
$ |
(11,006 |
) |
| Net loss per share, basic and diluted |
|
$ |
(0.03 |
) |
|
$ |
(0.02 |
) |
|
$ |
(0.05 |
) |
|
| Schedule of adjustments on the restated financial statements consolidated statement of cash flows |
| Consolidated Statement of Cash Flows for the Three Months Ended March 31, 2022 |
|
As
Previously
Reported |
|
|
Adjustment |
|
|
As
Restated |
|
| Net loss |
|
$ |
(6,000 |
) |
|
$ |
(3,978 |
) |
|
$ |
(9,978 |
) |
| Change in fair value of contingent consideration from mergers and acquisitions |
|
$ |
682 |
|
|
$ |
3,978 |
|
|
$ |
4,660 |
|
|